- Zhu, Rui;
- Xu, Longfa;
- Zheng, Qingbing;
- Cui, Yanxiang;
- Li, Shaowei;
- He, Maozhou;
- Yin, Zhichao;
- Liu, Dongxiao;
- Li, Shuxuan;
- Li, Zizhen;
- Chen, Zhenqin;
- Yu, Hai;
- Que, Yuqiong;
- Liu, Che;
- Kong, Zhibo;
- Zhang, Jun;
- Baker, Timothy S;
- Yan, Xiaodong;
- Zhou, Z Hong;
- Cheng, Tong;
- Xia, Ningshao
Coxsackievirus A10 (CVA10) recently emerged as a major pathogen of hand, foot, and mouth disease and herpangina in children worldwide, and lack of a vaccine or a cure against CVA10 infections has made therapeutic antibody identification a public health priority. By targeting a local isolate, CVA10-FJ-01, we obtained a potent antibody, 2G8, against all three capsid forms of CVA10. We show that 2G8 exhibited both 100% preventive and 100% therapeutic efficacy against CVA10 infection in mice. Comparisons of the near-atomic cryo-electron microscopy structures of the three forms of CVA10 capsid and their complexes with 2G8 Fab reveal that a single Fab binds a border region across the three capsid proteins (VP1 to VP3) and explain 2G8's remarkable cross-reactivities against all three capsid forms. The atomic structures of this first neutralizing antibody of CVA10 should inform strategies for designing vaccines and therapeutics against CVA10 infections.